NCT06258642View on ClinicalTrials.gov

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

NARecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Small Cell Lung Cancer Recurrent
Interventions
DRUG

Irinotecan Liposome

70 mg/m\^2 , d1, Q2W, iv

DRUG

Anlotinib

12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.

Trial Locations (1)

200032

RECRUITING

Cancer hospital Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER